Long-Term Debt and Other Financings - Novartis Note - Additional Information (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Jan. 31, 2014 |
May 31, 2005 |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Novartis Note [Member] | |||||
| Debt Instrument [Line Items] | |||||
| Maturity date | Jun. 30, 2015 | ||||
| Research and development expenses funded through loan facility, maximum | 75.00% | ||||
| Maximum borrowing capacity under loan agreement | $ 50,000,000 | ||||
| Interest rate at period end | 3.32% | ||||
| Accrued interest payable | $ 400,000 | $ 300,000 | $ 300,000 | ||
| Percentage of milestone received | 25.00% | ||||
| Milestone received under the collaboration agreement | $ 7,000,000 | ||||
| Repayment of debt | $ 1,750,000 | ||||
| Outstanding principal balance | $ 14,100,000 | $ 13,700,000 | |||
| Novartis Note [Member] | Six-month London Interbank Offered Rate [Member] | |||||
| Debt Instrument [Line Items] | |||||
| Basis spread on variable rate | 2.00% | ||||
| Secured Note Amendment [Member] | |||||
| Debt Instrument [Line Items] | |||||
| Maturity date | Sep. 30, 2020 | ||||
| Reduction in outstanding principal amount | $ 7,300,000 | ||||
| X | ||||||||||
- Definition Percentage points added to the reference rate to compute the variable rate on the debt instrument. No definition available.
|
| X | ||||||||||
- Definition Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Decrease for amounts of indebtedness forgiven by the holder of the debt instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Increase for accrued, but unpaid interest on the debt instrument for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. No definition available.
|
| X | ||||||||||
- Definition The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company. No definition available.
|
| X | ||||||||||
- Definition The maximum borrowing capacity for a debt instrument under the loan agreement. No definition available.
|
| X | ||||||||||
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. No definition available.
|
| X | ||||||||||
- Definition Refers to percentage of milestone received. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|